Boost Home Healthcare: Why Most Buyers Should Walk Away (and the One Who Shouldn't)

The Zorzee Report | Issue #4 | Home Care Series, Part 4 of 4

Note: this issue is based on the March 18, 2026 Boost Home Healthcare FDD. The filing contains no Item 19 financial performance representation, which is accurately represented here from the source.

Three issues in, you can read a home care FDD without breaking a sweat. You know the labor line is the whole game. You know the phone doesn't ring until you make it ring. You know the part-timer who went full-time and tripled his revenue. So Boost Home Healthcare, fourth in the series with "home" sitting right there in the name, looks like more of the same.

It isn't. It's a different business wearing a familiar word.

"Home" is the only thing Boost shares with One You Love and Seniors Helping Seniors. Everything under it is another animal: Medicare-certified, physician-ordered, billed to the federal government, and structurally allergic to paying you on time. You can't even open the doors until a state licensing board says you can, which can eat the better part of a year before you see a dollar. Different capital, different clock, different regulator, different operator. For most people reading this, the right move is to close the tab. This issue is about why, and about the one operator who should do the exact opposite.

Boost is a Medicare-certified skilled home health agency. The care is clinical and physician-ordered: home health aides, licensed practical and vocational nurses, registered nurses, physical, occupational, and speech therapy, medical social work (Item 1). A doctor has to order it. The patient has to clinically qualify. And the paperwork has to satisfy the federal government, which is exactly as relaxing as it sounds.

The bill doesn't go to the family. It goes to Medicare, Medicaid, or a commercial insurer.

That one fact rewires everything. This isn't a home care business that happens to be medical. It's a medical business that happens to visit homes. The federal government sets the terms: how you deliver the care, how you document it, and how long you wait to get paid for it. The upside is a customer that never goes bankrupt. The downside is a customer that pays strictly on its own schedule, and never yours.

Entry runs $162,650 to $337,750 for a single unit, $60,000 of it to the franchisor up front. A two-to-three-unit development deal runs $227,150 to $458,275, with $110,000 to $150,000 to the franchisor (Item 7). Those are the entry numbers. They're not the number that matters.

Every franchise decision comes down to one question: what do franchisees actually make? More often than not, the franchisor gives you a solid clue in the Item 19 financial performance section. But under the Federal Trade Commission's Franchise Rule, that disclosure is voluntary, and Boost took them up on the offer.

A missing Item 19 is a menu with no prices. You can still order. You just won't know what anything costs until the check arrives, and by then you've already eaten. It isn't automatically disqualifying. But it moves the entire burden of proof onto you. The financial picture you'd normally read off the page, you now have to build by phone. Here, those calls aren't extra credit. They're the whole assignment.

Item 20 hands you the list of current and former franchisees. That's your call sheet. Walk in asking for the things the document won't tell you: real revenue by year of operation. Real reimbursement rates by payer in your state. The real licensing timeline they lived. How much cash they burned between signing and their first Medicare check. How often their claims got denied. If those calls don't give you enough to build a credible model, you don't have what you need to sign. Full stop.

In private pay, the money's current. You deliver care, you invoice the family, you get paid. Boost doesn't work like that, and the gap between the two is where undercapitalized operators run aground.

You deliver the clinical care, document it to federal standard, code every encounter correctly, and submit the claim to a government payer on an episode-of-care basis (Item 1). Then you wait. The reimbursement lands well after the service, and a single denied claim pushes it out further. The whole time, you're carrying a medically staffed payroll, liability coverage, and compliance overhead, none of which care that you haven't been paid yet.

And that's after you're open. You can't open on day one. You apply for a state home health agency license, and in plenty of states you fight through a Certificate of Need just to be allowed to apply (Item 1). The FDD's special-risk section even has a heading for the problem, "Unopened Franchises," and the numbers back it up: 88 franchise agreements signed but not yet open as of December 31, 2025, against just 3 operating outlets (Item 20). A backlog of people who signed, paid, and are still sitting there waiting to open the doors.

How long is that wait? In my experience, six to eighteen months depending on the state. The filing won't put a number on it, so treat that range as mine, not a quote from Boost.

Now stack the two: a pre-revenue licensing window measured in months, then a government reimbursement cycle that pays well behind the work once you finally open. Size your capital off the Item 7 range, assume you're operating in 90 days, and you're not even close.

Most royalties are a single flat percentage. This one has a personality: it changes with who's paying the bill.

Item 6 sets it by payer. Medicare, commercial insurance, and private pay carry 5.0% of net revenue. Medicaid carries 3.5%. On top sits a 2% national marketing fee, plus other marketing and service fees.

Don't read the lower Medicaid tier as a discount. A royalty that scales with the payer is one that tracks what the payer actually pays, and Medicaid generally reimburses less per visit than Medicare. The 3.5% costs you less precisely because the revenue under it is worth less. Your payer mix drives both sides of the equation, what you collect and what you owe, and your payer mix is a function of your territory.

That makes territory selection a cost-structure call, not just a market-size one. Model your expected payer mix while you're still choosing a territory, not after you've signed for one.

Here's the turn. Everything that makes Boost miserable to get into is the same thing that protects you once you're in. The capital wall, the licensing window, the billing and clinical complexity, each one screens somebody out. The generalist who runs dry at month twelve waiting on a license never becomes your competitor, because he never opens the doors. Once you're licensed and Medicare-certified, you're standing inside a market with high regulatory walls around it. Nobody opens next door next month and takes your referrals, because nobody can.

That "nobody can" cuts both ways. It also keeps most people out, possibly you. The model fits a narrow operator. Someone who arrives with clinical leadership already in place, a Director of Nursing and a Medicare billing specialist on day one, not a month-six hire you go looking for after the patients start arriving. Someone who already knows the physicians, the discharge planners, the case managers, because those relationships are the patient pipeline. And someone with reserve capital well past the Item 7 range, sized to eat a year-plus of pre-revenue burn and the reimbursement lag on top of it.

For that operator, the complexity is the moat. The franchise just wraps a brand and a system around capabilities they spent a career building.

For everybody else, the gap between what this business demands and what a typical corporate buyer brings to it is the most important figure in the FDD. It's not in Item 19, because there is no Item 19. It's in the franchisee calls you make before you ever sign.

Boost is the newest brand in this series, and the ownership is institutional. Boost Franchise Systems sits under Best Life Brands in Troy, Michigan. Best Life is owned by CFC Holding Company, out of 45 Rockefeller Center in New York, and backed by the private equity firm The Riverside Company (Item 1). The CEO is J.J. Sorrenti (Item 2).

Read that as a trade, not a verdict. Private equity can push a franchisor toward unit count and systemwide revenue, the numbers that pretty up a valuation. The FDD's own special-risk section adds two more flags: a short operating history and a financial-condition risk. But institutional money can also pay for the billing technology, compliance systems, and clinical support that a Medicare business genuinely needs and a founder in a garage simply can't afford.

In a business where billing and compliance are the hardest problems you've got, that infrastructure is worth a lot, if it's real. Ask current franchisees what the billing and clinical support actually look like in the field, not in the pitch deck. Their answer tells you whether the institutional muscle is pointed at your success or at the next valuation.

One more for the file: Item 3 shows Boost sued a franchisee over unpaid fees in October 2025. A franchisor chasing a collection is routine, and a far different signal from franchisees suing the brand. But it's in the filing, so read it yourself.

Four issues, one category, four different answers.

Issue 1 made the case that the aging-population tailwind is real and beside the point. Issue 2 showed, in One You Love's own numbers, that what you do in year one decides year two, and that one part-timer who finally went full-time tripled to $1.49 million. Issue 3 showed how Seniors Helping Seniors quietly cut the biggest cost in the business, 53.3% labor against a 65-to-75% industry, with a single decision about who the caregiver is. And Issue 4 shows that the category runs all the way into Medicare-certified skilled care, which changes the capital, the timeline, the regulation, and the operator it takes to survive it.

The right brand, in the right category, for the right operator, is a defensible business with real cash flow. The wrong fit is an expensive education. The FDD is the document. The franchisees are the story. Read one. Call the others.

One more thing, for the Pro readers. The series gave you the four brands. Thursday, the next issue inverts them. It's the Pro-only Inversion Deep-Dive: I take the numbers that made you flinch across these four issues, the early royalty, the fast growth, the missing Item 19, the Year-1 grind, and flip each one to see whether the thing that scared you is actually the thing keeping weaker operators out. Same filings, read backward. If you're not on Pro yet, that's the one to join for. Lock In My Founding Rate — $9/month, locked for life. The founding rate closes July 2.

If you are looking at a home care or home health brand, or just interested in learning more about the category, that is what I do. I have read every FDD in this series. I can tell you in 15 minutes whether the numbers support the pitch. My consulting costs you nothing. Book the Free Zorzee Clarity Call.

Grab the free Five Signals Franchise Audit Guide at zorzee.com: 30 signals across 5 buckets that tell you whether any franchise document holds up. Royalty Burden, Unit Economics, Litigation Risk, Validation Risk, Term and Exit Risk. Same framework Zorzee applies to every brand.

Already own a franchise, or deep into the validation process and the numbers aren't matching what you were told? Books Brothers does a free 15-minute Cash Flow Audit. See how it works at booksbrothers.co.